

Teprasiran

Cat. No.:	HY-132595
CAS No.:	1231737-88-4
Molecular Weight:	12320
Sequence:	RNA, (G-Am-G-Am-A-Um-A-Um-U-Um-C-Am-C-Cm-C-Um-U-Cm-A), complex with RNA (Um-G-Am-A-Gm-G-Gm-U-Gm-A-Am-A-Um-A-Um-U-Cm-U-Cm) (1:1)
Target:	MDM-2/p53; Small Interfering RNA (siRNA)
Pathway:	Apoptosis; Epigenetics
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Teprasiran

SOLVENT & SOLUBILITY

In Vitro

H₂O : ≥ 20 mg/mL (1.62 mM)

* "≥" means soluble, but saturation unknown.

Solvent	Mass	Concentration		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	0.0812 mL	0.4058 mL	0.8117 mL
	5 mM	---	---	---
	10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Teprasiran (QPI-1002) is a small interfering RNA that temporarily inhibits p53-mediated cell death that underlies acute kidney injury (AKI)^[1].

In Vitro

Teprasiran is a synthetic, chemically stabilized small interfering RNA (siRNA) acting through RNA interference, which temporarily inhibits p53 expression for ≈48 to 72 hours^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Matthias Thielmann, et al. Teprasiran, a Small Interfering RNA, for the Prevention of Acute Kidney Injury in High-Risk Patients Undergoing Cardiac Surgery: A Randomized Clinical Study. *Circulation*. 2021;144:1133-1144.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA